Education
About Us
Working with TipRanks
Follow Us
Immunovia AB (IMMVF)
OTHER OTC:IMMVF
IMMVF Stock Chart & Stats
$0.05
-$0.10(-66.67%)
At close: 4:00 PM EST
$0.05
-$0.10(-66.67%)
Day’s Range― - ―
52-Week Range$0.02 - $0.04
Previous CloseN/A
Volume500.00
Average Volume (3M)0.00
Market Cap
$16.56M
Enterprise Value$93.16M
Total Cash (Recent Filing)$26.57M
Total Debt (Recent Filing)$20.37M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Feb 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding672,666,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.87
Price to Sales (P/S)48.45
P/FCF Ratio-0.47
Enterprise Value/Market Cap5.63
Enterprise Value/Revenue118.67
Enterprise Value/Gross Profit-3.13
Enterprise Value/Ebitda-1.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Immunovia AB News
IMMVF FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was $0.02 and its highest was $0.04 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is $16.56M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Feb 24, 2026 which is in 51 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Nov 26, 2025. The company reported -$0.008 earnings per share for the quarter, missing the consensus estimate of -$0.005 by -$0.003.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is >-0.01.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -$0.008 in its last earnings report, missing expectations of -$0.005. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in IMMVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMVF Company Deck
IMMVF Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reveals significant progress in Immunovia's commercial transition and positive initial market response to PancreaSure, alongside key milestones in reimbursement rate setting. However, uncertainties remain regarding coverage and revenue timelines.View all IMMVF earnings summariesTechnical Analysis
Alligator Bioscience AB
―
Prostatype Genomics AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―
Ownership Overview
―
Insiders
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---